Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
An announcement from Aurora Cannabis ( (TSE:ACB) ) is now available.
Aurora Cannabis reported its fiscal 2025 third-quarter results with a total net revenue of $88.2 million, marking a 37% increase year-over-year, primarily driven by a 51% rise in its global medical cannabis sector. The company achieved record net income of $31.2 million and adjusted EBITDA of $23.1 million, both experiencing substantial growth. Aurora also generated positive free cash flow of $27.4 million, maintaining a strong balance sheet with $180 million in cash and a debt-free cannabis business. These results underscore Aurora’s leadership in the global cannabis industry, supported by international revenue growth and expansion in its plant propagation segment.
More about Aurora Cannabis
Aurora Cannabis Inc. is a leading global medical cannabis company based in Canada. It focuses on producing and selling medical cannabis products, with a significant emphasis on international markets.
YTD Price Performance: -18.22%
Average Trading Volume: 872,343
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $193.1M
For a thorough assessment of ACB stock, go to TipRanks’ Stock Analysis page.
